Suzhou Zelgen Biopharmaceuticals Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2009-03-18
- Employees
- 867
- Market Cap
- -
- Website
- https://www.zelgen.com
Clinical Trials
73
Active:4
Completed:30
Trial Phases
3 Phases
Phase 1:42
Phase 2:19
Phase 3:12
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (73 trials with phase data)• Click on a phase to view related trials
Phase 1
42 (57.5%)Phase 2
19 (26.0%)Phase 3
12 (16.4%)ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Phase 1
Not yet recruiting
- Conditions
- Small Cell Lung CancerNeuroendocrine Carcinoma
- Interventions
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 350
- Registration Number
- NCT07038096
Study of ZG006 in Participants With Neuroendocrine Prostate Cancer
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT07024277
- Locations
- 🇨🇳
Fudan university shanghai cancer center, Shanghai, Shanghai, China
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Biological: ZGGS18 for InjectionBiological: ZG005 for Injection
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT06938880
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Study of ZG005 in Patients With Advanced Solid Tumors
Phase 2
Not yet recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Biological: ZG005 for Injection
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 100
- Registration Number
- NCT06927687
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
Phase 1
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Biological: ZG005 for InjectionDrug: Gecacitinib Hydrochloride Tablets
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 50
- Registration Number
- NCT06903377
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 15
- Next
News
No news found